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Abstract
Context—In June 2009, the World Health Organization officially declared an influenza 
pandemic. In the United States, the federal government supplied 2009 H1N1 vaccine at no cost 
and provided funding for states to implement vaccination programs. Vaccine providers including 
health departments were permitted to bill insurance plans for administering 2009 H1N1 vaccine.
Objective—To determine the extent to which local health departments (LHDs) billed for 
administering 2009 H1N1 vaccine, specific billing practices of LHDs, and factors associated with 
LHD billing.
Design—Cross-sectional study using an Internet-based survey, and semistructured interviews.
Participants and Setting—Nationally representative stratified random sample of 527 LHDs in 
the United States. Interviews were conducted among a convenience sample of LHDs.
Main Outcome Measure—Proportion of LHDs reporting billing for administering 2009 H1N1 
vaccine.
Results—A total of 308 health departments (58%) provided responses complete enough for 
analysis. Most LHDs (82%) had previous experience billing for seasonal influenza vaccination, 
but only 20% (n = 57) billed for administration of 2009 H1N1 vaccine. Medicare (74%) and 
Medicaid (80%) were the most commonly billed health care payers; more than half (55%) of 
LHDs billing for 2009 H1N1 vaccine administration sought reimbursement from one or more 
private insurance plans. Billing for 2009 H1N1 vaccine administration was more common among 
LHDs that previously offered seasonal influenza vaccination (P = .003), previously billed for 
seasonal influenza vaccination (P = .04), and conducted school-located influenza vaccination 
clinics prior to the 2009–2010 influenza season (P = .002).
Conclusions—Most LHDs elected not to bill for 2009 H1N1 vaccine administration despite 
prior experience billing for influenza vaccination. It is important to understand barriers to billing 
and resources needed by LHDs to facilitate billing for vaccination. Developing public health 
billing capacity will allow LHDs to recoup the costs of providing vaccines to insured persons and 
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may also prepare them to conduct billing activities for other services or during future public health 
emergencies.
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In April 2009, 2 cases of respiratory illness reported to the Centers for Disease Control and 
Prevention (CDC) were determined to be caused by a novel influenza virus.1 By May 6, 
2009, 1487 probable and confirmed cases of 2009 pandemic influenza A (H1N1) (pH1N1) 
infection had been reported in the United States2; on June 11, 2009, the World Health 
Organization officially declared a pandemic. The Food and Drug Administration approved 
vaccines against pH1N1 virus for use in the United States on September 15, 2009.3
Beginning in June 2009, state and local health departments (LHDs) worked with the federal 
government to implement a pandemic response based, in part, on previously developed 
pandemic response plans. The 2009 H1N1 vaccination program was a public-private 
partnership: The federal government provided vaccine to states at no cost, so providers were 
not permitted to bill third-party payers for the vaccine itself; however, private providers 
could bill for vaccine administration.4 Government health programs including Medicare, 
Medicaid, TRICARE, and the Veterans’ Administration, and many private health insurers, 
covered the cost of 2009 H1N1 vaccine administration for beneficiaries.
Initially, it was unclear whether public providers like LHDs would be permitted to bill 
administration fees. Multiple rounds of the CDC’s Public Health Emergency Response 
(PHER) funding were made available to states to support implementation of H1N1 
vaccination programs; states could allocate PHER funds to LHDs at their discretion. 
Because PHER funding amounts were initially unknown, some LHDs expressed concern 
about having adequate funds for H1N1 vaccination programs if they could not bill for 
vaccine administration. Ultimately billing of third-party payers was permitted, although 
LHDs were required to vaccinate all persons regardless of ability to pay.5
The National Association of County and City Health Officials, in collaboration with the 
CDC, conducted a survey to understand policies and strategies used by LHDs during the 
pandemic response. This report describes the prevalence of billing and factors associated 
with billing for 2009 H1N1 vaccine administration.
Methods
Survey
A nationally representative sample was selected from all US LHDs (N = 2794) using 
stratified random sampling with replacement from 7 strata based on service population size. 
Local health departments in the largest population stratum (serving ≥1 million people) were 
oversampled; 527 LHDs were selected. The self-administered Internet-based questionnaire 
included allocation, distribution, and management of 2009 H1N1 vaccine supply; 
communication between LHDs, providers, and state health departments; use of school-
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located clinics to administer 2009 H1N1 vaccine; and practices related to billing for 2009 
H1N1 vaccine administration. The survey was fielded from June to August 2010.
Data presented later focus on LHD billing practices for 2009 H1N1 vaccine administration. 
Analysis was performed using SAS 9.2 (SAS Institute, Cary, North Carolina) and SUDAAN 
10.0.1. Cochran-Mantel-Haenszel χ2 analysis was used to test associations between LHD 
characteristics and the decision to bill for 2009 H1N1 vaccine administration.
Of 527 sampled LHDs, 336 (64%) responded. Of these, 28 LHDs were excluded for high 
item nonresponse, leaving 308 surveys (58%) for analysis. Responding LHDs represented 
45 states, with 1 to 20 LHDs per state. Results were weighted to account for sampling 
scheme and differences in nonresponse by stratum. Unweighted frequencies and weighted 
proportions are presented.
Interviews
Independent of the survey, the CDC contacted a convenience sample of LHDs known to 
have billed for 2009 H1N1 vaccine administration. Between February and November 2010, 
the author conducted semistructured telephone interviews with 9 LHDs using a standardized 
list of questions, including which payers were billed and in which settings, prior experience 
billing for vaccinations and how this informed billing activities for 2009 H1N1 vaccine, how 
insurance information was collected and processed, estimated proportions of vaccinations 
billed for which claims were paid, and barriers and facilitators to billing for 2009 H1N1 
vaccine administration. After each interview, the author provided a written summary to the 
LHD for review. Common themes are presented later.
Results
Survey
Prior to the 2009–2010 influenza pandemic, most (82%) responding LHDs offering seasonal 
influenza vaccine had billed third-party payers for influenza vaccine administration. 
However, only 20% (n = 57) of the 297 respondents that offered 2009 H1N1 vaccine 
reported billing for its administration (the Table). Among those 57 LHDs, the most 
commonly billed payers were Medicare (74%) and Medicaid (80%); 55% billed one or more 
private insurance plans. A majority of LHDs billing for 2009 H1N1 vaccine administration 
billed for vaccines given at public health department clinics (80%) and community mass 
vaccination events (51%); nearly half (46%) also billed for administering vaccines at school-
located vaccination clinics (the Table). Roster billing— submitting a single claim for 
multiple beneficiaries-–was reported by only 37% of billing LHDs, primarily for Medicare 
billing. Nearly one-third of LHDs billing for 2009 H1N1 vaccine administration did not 
know whether roster billing was used.
In bivariate analysis, billing for 2009 H1N1 vaccine administration was more common 
among LHDs that previously offered seasonal influenza vaccination (21% vs 3%, P = .003), 
previously billed for seasonal influenza vaccination (23% vs 11%, P = .04), and previously 
conducted school-located influenza vaccination clinics (30% vs 14%, P = .002). No 
difference in 2009 H1N1 billing practices was observed among LHDs serving different 
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population sizes. Local health departments serving fewer than 50 000 people were more 
likely than those serving midsize populations to have billed Medicare for seasonal influenza 
vaccination prior to the 2009–2010 season (97% vs 87%, P = .01).
Interviews
All LHDs interviewed had prior billing experience. 2009 H1N1 billing practices varied; 
some LHDs billed only insurance plans with which billing arrangements already existed, 
others established relationships with additional plans to bill for 2009 H1N1 vaccine 
administration. Methods for collecting and processing insurance information also varied, 
although several LHDs described using existing electronic systems to facilitate creation and 
submission of insurance claims. Most LHDs estimated 70% to 90% of claims submitted for 
2009 H1N1 vaccine administration were paid, although some claims had yet to be processed 
by the insurance plans billed. Factors cited as facilitating billing for 2009 H1N1 vaccine 
administration included prior billing experience, contracting with organizations familiar 
with insurance billing or hiring staff specifically for billing, and providing billing training to 
existing staff. Factors cited as barriers included variable benefits coverage and billing 
practices among private insurers, the need to revise existing systems to accommodate 2009 
H1N1 vaccine billing, and difficulty understanding the CDC’s billing guidance.
Comment
Overall, 20% of LHDs responding to the survey reported billing for 2009 H1N1 vaccine 
administration. Medicare and Medicaid were most commonly billed; more than half of 
LHDs that billed for 2009 H1N1 vaccine administration reported billing at least 1 private 
insurance plan. Although the majority of LHDs responding to the survey reported prior 
experience billing for seasonal influenza vaccination, most did not bill for 2009 H1N1 
vaccine administration.
There are several reasons LHDs may have elected not to bill for 2009 H1N1 vaccine 
administration. First, for some LHDs, PHER funds may have been adequate to cover the 
costs of implementing mass 2009 H1N1 vaccination programs. Second, the CDC did not 
distribute guidance on financing and billing for 2009 H1N1 vaccination until October 1, 
2009 (M.C.L., written communication, October 1, 2009). Although LHDs were not yet 
vaccinating, the delayed guidance may have limited their ability to plan for billing before 
beginning vaccination efforts. Finally, billing for 2009 H1N1 administration may have been 
too resource intensive for LHDs to undertake during the early pandemic response, 
particularly if new contracts between LHDs and insurance plans needed to be established. 
Interviewed LHDs indicated hiring additional staff and providing training were important 
factors contributing to successful billing; resources for such activities may not have been 
available at all LHDs.
Among LHDs that did bill for 2009 H1N1 vaccine administration, billing was broadly 
implemented, with many LHDs reporting in the survey and interviews billing both public 
and private payers and billing in a variety of settings. Interviews with LHDs that billed for 
2009 H1N1 vaccine administration indicated systems used to collect and process insurance 
information were generally successful, and most LHDs felt billing efforts had been 
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worthwhile. These findings suggest that, once established, billing practices may be used for 
a variety of insurers and settings. However, some LHDs interviewed were unsure whether 
they would continue additional billing efforts in the 2010–2011 influenza season, primarily 
due to resource concerns.
Study results are subject to certain limitations and may not be generalizable to LHDs 
nationally. Local health departments responding to the survey may differ from 
nonresponders in ways that were unmeasured. Nonresponse weighting can reduce but not 
eliminate potential bias. Second, interview data were gathered only from a small number of 
LHDs. Finally, the extent of private insurance billing cannot be fully quantified as survey 
respondents were asked whether they billed private insurance but not the number of plans 
billed.
During the 2009–2010 influenza season, survey data indicate LHDs that billed for 2009 
H1N1 vaccination utilized billing processes across a variety of insurance plans and settings. 
However, few LHDs responding to the survey chose to bill for 2009 H1N1 vaccine 
administration despite prior experience. Previous billing experience may reduce the level of 
effort needed to establish or amend billing relationships with insurance plans, but billing 
remains a challenge for LHDs.6 Beginning with the American Recovery and Reinvestment 
Act of 2009, several states have received funding for planning and developing vaccination 
billing processes in state and LHDs.7 Continuing to develop public health billing capacity 
for influenza vaccination and other vaccines for children and adults will allow LHDs to 
recoup the costs of vaccinating insured persons,8 and may also prepare them to bill for 
routine services and during future public health emergencies.
Acknowledgments
The author thanks Fan Zhang, MD, PhD, MPH, and Pascale Wortley, MD, MPH, of the Centers for Disease 
Control and Prevention for their guidance; the National Association of County and City Health Officials for their 
collaboration on this survey; and the local health departments for their time in completing the survey and 
interviews.
References
1. Centers for Disease Control and Prevention. Swine influenza A (H1N1) infection in two children—
Southern California, March–April 2009. MMWR Morb Mortal Wkly Rep. 2009; 58(15):400–402. 
[PubMed: 19390508] 
2. Centers for Disease Control and Prevention. Update: novel influenza A (H1N1) virus infections—
Worldwide, May 6, 2009. MMWR Morb Mortal Wkly Rep. 2009; 58(17):453–458. [PubMed: 
19444146] 
3. Centers for Disease Control and Prevention. Update on influenza A (H1N1) 2009 monovalent 
vaccines. MMWR Morb Mortal Wkly Rep. 2009; 58(39):1100–1101. [PubMed: 19816398] 
4. Centers for Disease Control and Prevention. Questions and answers on 2009 H1N1 vaccine 
financing. Archived Web page. Updated November 30, 2009. http://www.cdc.gov/H1N1flu/
vaccination/statelocal/vaccine_financing.htm. Accessed November 10, 2011
5. Centers for Disease Control and Prevention. H1N1 vaccine administration billing Q & As. Archived 
Web page. Updated October 20, 2009. http://www.cdc.gov/H1N1flu/vaccination/statelocal/
vaccing_billing_qa.htm. Accessed November 10, 2011
Lindley Page 5













6. Penfold RB, Rusinak D, Lieu TA, Shefer A, Messonnier M, Lee GM. Financing and systems 
barriers to seasonal influenza vaccine delivery in community settings. Vaccine. 2011; 29:9632–
9639. [PubMed: 22036886] 
7. Rodewald, LE. An immunization safety net without missed opportunities: status of the public sector 
billing project; Presented at: Meeting of the National Vaccine Advisory Committee; September 
2011; Washington DC. 
8. Quintanilla C, Duncan L, Luther L. Billing third-party payers for vaccines: state and local health 
department perspectives. J Public Health Manag Pract. 2009; 15(5):E1–E5. [PubMed: 19704301] 
Lindley Page 6



























Billing Practices of Local Health Departments Related to 2009 H1N1 Vaccine Administration (n = 308)a
% (n)
LHD provided 2009 H1N1 vaccine
 Yes 96.5 (297)
 No   3.5 (11)
LHD billed third-party payers for 2009 H1N1 vaccine administrationb
 Yes 20.0 (57)
 No 80.0 (240)
Which third-party payers did LHDs bill for 2009 H1N1 vaccine administration?c
  Medicare 73.8 (44)
  Medicaid 79.8 (46)
  TRICARE 10.8 (7)
  ≥1 private insurance plans 55.0 (33)
  Other   4.8 (3)
  Don’t know   6.9 (4)
In which types of clinics did LHDs bill third-party payers?c
  Routine public health clinics 80.0 (45)
  School-located clinics 45.9 (26)
  Mass vaccination clinics 51.0 (30)
  Other 11.6 (6)
  Don’t know 10.1 (5)
Did LHDs use roster billing with any third-party payers?c
  Yes 37.2 (19)
  No 32.4 (20)
  Don’t know 30.5 (18)
 Third-party payers for which LHDs used roster billingd
  Medicare 85.3 (16)
 Medicaid 33.4 (6)
  ≥1 private insurance plans 13.1 (3)
LHD provided seasonal influenza vaccine prior to 2009–2010
  Yes 92.8 (284)
  No   7.2 (22)
LHD billed third-party payers for seasonal influenza vaccine administration prior to 2009–2010e
  Yes 82.4 (230)
  No 17.6 (52)
Which third-party payers did LHDs bill for seasonal influenza vaccine administration?f
  Medicare 93.7 (211)
  Medicaid 69.9 (162)
  TRICARE   8.9 (20)
  ≥1 private insurance plans 39.4 (92)















  Other   6.9 (15)
  Don’t know   0.7 (3)
Abbreviation: LHD, local health department.
a
The table presents unweighted Ns and weighted proportions. “Don’t know” responses are combined with “no” responses for all yes/no questions 
where fewer than 10% of respondents selected “don’t know.” One respondent did not respond to the question about in which types of clinics did 
LHDs bill, and 2 did not respond to the questions about providing influenza vaccine and billing for influenza vaccination prior to the 2009–2010 
influenza season.
b
Analysis restricted to the 297 LHDs that provided 2009 H1N1 vaccine in any clinic during the 2009–2010 influenza season.
c
Analysis restricted to the 57 LHDs that reported billing third-party payers for 2009 H1N1 vaccination. Multiple responses to questions about 
payers and clinic types were possible, so proportions for these questions may sum to greater than 100%.
d
Analysis restricted to the 19 LHDs that reported using roster billing for 2009 H1N1 vaccination. Multiple responses to this question were possible, 
so proportions may sum to greater than 100%.
e
Analysis restricted to the 284 LHDs that reported providing seasonal influenza vaccination prior to the 2009–2010 influenza season.
f
Analysis restricted to the 230 LHDs that reported billing third-party payers for seasonal influenza vaccination prior to the 2009-2010 season.
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